Adjuvant therapy in renal cell carcinoma: the perspective of urologists

ConclusionsA minority of urologists would use AT and are more confident in ASSURE-trial. Reluctance of prescribing AT mainly is based on lack of OS data and conflicting trial results.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research